307 related articles for article (PubMed ID: 24836834)
1. Nonalcoholic Fatty liver disease in renal transplant recipients proven by transient elastography.
Mikolasevic I; Racki S; Lukenda V; Milic S; Pavletic-Persic M; Orlic L
Transplant Proc; 2014 Jun; 46(5):1347-52. PubMed ID: 24836834
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease.
Mikolasevic I; Orlic L; Zaputovic L; Racki S; Cubranic Z; Anic K; Devcic B; Stimac D
Wien Klin Wochenschr; 2015 Jun; 127(11-12):451-8. PubMed ID: 25854911
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease (NAFLD) and cardiovascular risk in renal transplant recipients.
Mikolasevic I; Racki S; Zaputovic L; Lukenda V; Sladoje-Martinovic B; Orlic L
Kidney Blood Press Res; 2014; 39(4):308-14. PubMed ID: 25300437
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography.
Mikolasevic I; Racki S; Bubic I; Jelic I; Stimac D; Orlic L
Kidney Blood Press Res; 2013; 37(4-5):305-10. PubMed ID: 24029696
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
6. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease.
Orlic L; Mikolasevic I; Lukenda V; Anic K; Jelic I; Racki S
Wien Klin Wochenschr; 2015 May; 127(9-10):355-62. PubMed ID: 25412597
[TBL] [Abstract][Full Text] [Related]
8. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
[TBL] [Abstract][Full Text] [Related]
10. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive characterization of graft steatosis after liver transplantation.
Karlas T; Kollmeier J; Böhm S; Müller J; Kovacs P; Tröltzsch M; Weimann A; Bartels M; Rosendahl J; Mössner J; Berg T; Keim V; Wiegand J
Scand J Gastroenterol; 2015 Feb; 50(2):224-32. PubMed ID: 25429378
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease.
Mikolasevic I; Orlic L; Milic S; Lukenda V; Racki S; Stimac D; Avdovic E; Zaputovic L
Wien Klin Wochenschr; 2014 Aug; 126(15-16):474-9. PubMed ID: 24652022
[TBL] [Abstract][Full Text] [Related]
13. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease.
Alkhouri N; Sedki E; Alisi A; Lopez R; Pinzani M; Feldstein AE; Nobili V
Liver Int; 2013 Jan; 33(1):79-85. PubMed ID: 23146095
[TBL] [Abstract][Full Text] [Related]
14. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
Mikolasevic I; Orlic L; Franjic N; Hauser G; Stimac D; Milic S
World J Gastroenterol; 2016 Aug; 22(32):7236-51. PubMed ID: 27621571
[TBL] [Abstract][Full Text] [Related]
15. Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification.
You SC; Kim KJ; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
J Gastroenterol Hepatol; 2015 Oct; 30(10):1536-42. PubMed ID: 25973647
[TBL] [Abstract][Full Text] [Related]
16. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
17. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease.
Aykut UE; Akyuz U; Yesil A; Eren F; Gerin F; Ergelen R; Celikel CA; Yilmaz Y
Scand J Gastroenterol; 2014 Nov; 49(11):1343-8. PubMed ID: 25259621
[TBL] [Abstract][Full Text] [Related]
18. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.
Mikolasevic I; Milic S; Racki S; Zaputovic L; Stimac D; Radic M; Markic D; Orlic L
Perit Dial Int; 2016; 36(4):427-32. PubMed ID: 26475841
[TBL] [Abstract][Full Text] [Related]
20. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: Lesson learnt from tertiary referral center.
Sandra S; Lesmana CRA; Purnamasari D; Kurniawan J; Gani RA
Diabetes Metab Syndr; 2019; 13(1):424-428. PubMed ID: 30641737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
